132 related articles for article (PubMed ID: 10476942)
1. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group.
Ship JA; Fox PC; Michalek JE; Cummins MJ; Richards AB
J Interferon Cytokine Res; 1999 Aug; 19(8):943-51. PubMed ID: 10476942
[TBL] [Abstract][Full Text] [Related]
2. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
3. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome.
Shiozawa S; Tanaka Y; Shiozawa K
J Interferon Cytokine Res; 1998 Apr; 18(4):255-62. PubMed ID: 9568728
[TBL] [Abstract][Full Text] [Related]
4. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results.
Cummins MJ; Papas A; Kammer GM; Fox PC
Arthritis Rheum; 2003 Aug; 49(4):585-93. PubMed ID: 12910567
[TBL] [Abstract][Full Text] [Related]
5. A third study on the use of orally administered anhydrous crystalline maltose for relief of dry mouth in primary Sjögren's syndrome.
Fox PC; Cummins MJ; Cummins JM
J Altern Complement Med; 2002 Oct; 8(5):651-9. PubMed ID: 12470447
[TBL] [Abstract][Full Text] [Related]
6. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial.
Sugai S; Takahashi H; Ohta S; Nishinarita M; Takei M; Sawada S; Yamaji K; Oka H; Umehara H; Koni I; Sugiyama E; Nishiyama S; Kawakami A
Mod Rheumatol; 2009; 19(2):114-24. PubMed ID: 19089532
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
[TBL] [Abstract][Full Text] [Related]
9. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.
Streckfus C; Bigler L; Navazesh M; Al-Hashimi I
Clin Oral Investig; 2001 Jun; 5(2):133-5. PubMed ID: 11480812
[TBL] [Abstract][Full Text] [Related]
10. Use of orally administered anhydrous crystalline maltose for relief of dry mouth.
Fox PC; Cummins MJ; Cummins JM
J Altern Complement Med; 2001 Feb; 7(1):33-43. PubMed ID: 11246934
[TBL] [Abstract][Full Text] [Related]
11. A preliminary study on the interferon-alpha treatment for xerostomia of Sjögren's syndrome.
Shiozawa S; Morimoto I; Tanaka Y; Shiozawa K
Br J Rheumatol; 1993 Jan; 32(1):52-4. PubMed ID: 8422560
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
[TBL] [Abstract][Full Text] [Related]
14. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome.
Kiliç H; Zeytin HE; Korkmaz C; Mat C; Gül A; Coşan F; Dinç A; Simşek I; Süt N; Yazici H
Rheumatology (Oxford); 2009 Nov; 48(11):1388-91. PubMed ID: 19717547
[TBL] [Abstract][Full Text] [Related]
15. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
[TBL] [Abstract][Full Text] [Related]
16. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome.
Pillemer SR; Brennan MT; Sankar V; Leakan RA; Smith JA; Grisius M; Ligier S; Radfar L; Kok MR; Kingman A; Fox PC
Arthritis Rheum; 2004 Aug; 51(4):601-4. PubMed ID: 15334433
[TBL] [Abstract][Full Text] [Related]
17. Mucin-containing lozenges in the treatment of intraoral problems associated with Sjögren's syndrome. A double-blind crossover study in 42 patients.
Gravenmade EJ; Vissink A
Oral Surg Oral Med Oral Pathol; 1993 Apr; 75(4):466-71. PubMed ID: 8464611
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren's syndrome.
Garlapati K; Kammari A; Badam RK; B E S; Boringi M; Soni P
Immunopharmacol Immunotoxicol; 2019 Apr; 41(2):312-318. PubMed ID: 30932714
[No Abstract] [Full Text] [Related]
19. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial.
Alves MB; Motta AC; Messina WC; Migliari DA
Quintessence Int; 2004 May; 35(5):392-6. PubMed ID: 15130080
[TBL] [Abstract][Full Text] [Related]
20. [Interferon alpha (IFNalpha) treatment for Sjögren's syndrome].
Shiozawa K; Shiozawa S
Nihon Rinsho; 2006 Jul; 64(7):1345-53. PubMed ID: 16838655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
